Takeda's dengue vaccine candidate shows efficacy in children aged 4 to 16, regardless of previous exposure to dengue fever

               08. (************.) 2019 Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) (“Takeda”) announced today that results from the primary endpoint analysis of the ongoing pivotal Phase 3 trial include Tetravalent Immunization Against Dengue Efficacy Study (TIDES) his dengue vaccine candidate (TAK – 003) were published in the New England Journal of Medicine. Takeda’s dengue vaccine candidate provided protection against virologically confirmed dengue fever (VCD), which was the primary endpoint of the study in children aged four to 16 years. The vaccine efficacy (VE) was 80, 2 percent (95% confidence interval [KI]: 73, 3% to 85, 3%; p
Read More

LEAVE A REPLY

Please enter your comment!
Please enter your name here